Clinical Evidence
The HelioLiver test delivers superior performance characteristics when compared to traditional testing for HCC
Clinical Evidence
A New Solution for Early Cancer Detection

The HelioLiver test delivers superior performance characteristics when compared to traditional blood tests for hepatocellular carcinoma.

HELIOLIVER
91% Specificity
AFPGALAD
Early Stage Sensitivity76%57%65%
Overall Sensitivity85%62%75%
Our Scientific Advisors
Richard Van Etten, MD, PhD

Richard Van Etten, MD, PhD

Chief Medical Advisor

Wei Li,PhD

Wei Li,PhD

Chief Bioinformatics Advisor

Mindie Nguyen, MD, MAS, AGAF

Mindie Nguyen, MD, MAS, AGAF, FAASLD

Hepatology Advisor and Lead Principal Investigator in CLiMB

Robert Gish, MD

Robert Gish, MD

The Hepatitis B Foundation

Our Clinical Trials

We are dedicated to continued evidence generation on the HelioLiver test. Helio Genomics is currently engaged in multiple pivotal, multi-center trials in the US and China.

Picture scientists in lab
CLiMB

Recruiting

A multi-center, prospective study conducted in the US to compare the sensitivity and specificity of the HelioLiver Test with ultrasound within a population at high risk of HCC due to liver cirrhosis.

Picture scientists in lab
FAST

Recruiting

A prospective RO1 study sponsored by NCI in collaboration with Mount Sinai and other medical institutions on the US to evaluate novel screening modalities and biomarkers.

Picture scientists in lab
ENCORE

Completed

A study to define the performance characteristics of the HelioLiver Test within a study population of subjects that have been diagnosed with liver cancer at various stages (I to IV).

Picture scientists in lab
HEPATIC

In Progress

A large-scale multi-center study to evaluate the performance characteristics of the HelioLiver test within a population of subjects diagnosed with HCC and surveillance subjects with liver disease.

Publications
We believe in sharing our learnings with the scientific community in order to achieve our common goal of advancing early cancer detection technology. We are proud to share the following publications.

Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma

Rui-Hua Xu, Wei Wei, Michal Krawczyk, Wenqiu Wang, Huiyan Luo, Ken Flagg, Shaohua Yi...

Nature, October 2017

Cellular Heterogeneity-Adjusted cLonal Methylation (CHALM) improves prediction of gene expression

Jianfeng Xu, Jiejun Shi, Xiaodong Cui, Ya Cui, Jingyi Jessica Li, Ajay Goel, Xi Chen, Jean-Pierre Issa, Jianzhong Su, Wei Li

Nature, January 2021

DNA methylation markers for diagnosis and prognosis of common cancers

Xiaoke Hao, Huiyan Luo, Michal Krawczyk, Wei Wei, Wenqiu Wang, Juan Wang, Ken Flagg, Jiayi Hou, Heng Zhang, Shaohua Yi...

PubMed, June 2017